Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

While some topical herbal therapies may provide benefit for patients with AD, systemic herbal therapies do not provide significant benefit.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc.

A recent study reveals that a novel postbiotic supplement, Pet Immune, significantly alleviates itching and enhances skin and ...

Eczema — also known as atopic dermatitis — is a common condition that can cause red, itchy, and inflamed skin. Although eczema can affect anyone, it’s especially common among children.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

On June 26, Arcutis Biotherapeutics Inc. announced that ZORYVE (roflumilast) cream 0.15% received a strong recommendation in ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...